Using artificial intelligence to pinpoint tumour cells with reduced ability to repair their own DNA can help identify tens of thousands of patients who would benefit from treatment with drugs from AstraZeneca Plc and GlaxoSmithKline Plc, researchers said.
Analysing genetic tests with a machine-learning algorithm helps target cancers that are vulnerable to treatment with drugs called PARP inhibitors, according to a study from scientists at Harvard Medical School in Boston and the UK’s University of Cambridge.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!